top of page

Carvedilol

Grade

Myxomatous Mitral Valve Disease Stage-B (MMVD-B)

Therapeutics

​

Evidence

​

  1. Choi, E.-K., Shen, M.J., Lin, S.-F., Chen, P.-S., Oh, S., 2014. Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. Europace 16, 1083–1091. https://doi.org/10.1093/europace/eut364

  2. Gordon, S.G., Arsenault, W.G., Longnecker, M., Boothe, D.M., Miller, M.W., Chalkley, J., 2006. Pharmacodynamics of Carvedilol in Conscious, Healthy Dogs. Journal of Veterinary Internal Medicine 20, 297–304. https://doi.org/10.1111/j.1939-1676.2006.tb02860.x

  3. Gordon, S.G., Saunders, A.B., Hariu, C.D., Boggess, M.M., Miller, M.W., 2012. Retrospective review of carvedilol administration in 38 dogs with preclinical chronic valvular heart disease. Journal of Veterinary Cardiology, The Mitral Valve 14, 243–252. https://doi.org/10.1016/j.jvc.2012.01.007

  4. Kang, M.-H., Park, H.-M., 2012. Application of carvedilol in a dog with pseudoephedrine toxicosis-induced tachycardia. Can Vet J 53, 783–786.

  5. Kishihara, J., Niwano, S., Niwano, H., Aoyama, Y., Satoh, A., Oikawa, J., Kiryu, M., Fukaya, H., Masaki, Y., Tamaki, H., Izumi, T., Ako, J., 2014. Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation. Cardiovasc Diagn Ther 4, 28–35. https://doi.org/10.3978/j.issn.2223-3652.2014.02.03

  6. Marcondes-Santos, M., Mansur, A.P., Fragata, F.S., Strunz, C.M.C., 2015. Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease. Braz J Med Biol Res 48, 886–894. https://doi.org/10.1590/1414-431X20154568

  7. Marcondes-Santos, M., Tarasoutchi, F., Mansur, A.P., Strunz, C.M.C., 2007. Effects of Carvedilol Treatment in Dogs with Chronic Mitral Valvular Disease. Journal of Veterinary Internal Medicine 21, 996–1001. https://doi.org/10.1111/j.1939-1676.2007.tb03055.x

  8. Nakamura, T., Fujita, T., Kishimura, M., Suita, K., Hidaka, Y., Cai, W., Umemura, M., Yokoyama, U., Uechi, M., Ishikawa, Y., 2016. Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy. Circ J 80, 2496–2505. https://doi.org/10.1253/circj.CJ-16-0736

Monograph Details

​

bottom of page